济川药业
(600566)
| 流通市值：258.30亿 | | | 总市值：259.17亿 |
| 流通股本：9.19亿 | | | 总股本：9.22亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,207,498,577.63 | 6,218,642,450.8 | 3,932,057,245.53 | 2,748,717,966.21 |
| 营业收入 | 1,207,498,577.63 | 6,218,642,450.8 | 3,932,057,245.53 | 2,748,717,966.21 |
| 二、营业总成本 | 832,970,181.7 | 4,311,082,171.03 | 2,887,618,682.39 | 2,042,988,755.57 |
| 营业成本 | 215,847,438.23 | 1,308,731,493.58 | 932,609,817.16 | 668,448,217.04 |
| 税金及附加 | 19,663,690.07 | 112,911,535.11 | 75,327,723.7 | 53,915,862.37 |
| 销售费用 | 415,600,503.12 | 2,110,818,556.06 | 1,338,590,972.63 | 976,858,157.57 |
| 管理费用 | 115,706,344.68 | 448,010,629.84 | 323,849,037.19 | 209,600,908.03 |
| 研发费用 | 106,827,557.37 | 385,101,963.67 | 271,853,927.95 | 189,893,896.33 |
| 财务费用 | -40,675,351.77 | -54,492,007.23 | -54,612,796.24 | -55,728,285.77 |
| 其中:利息费用 | 6,168,833.51 | 11,447,311.68 | 9,411,741.46 | 7,057,473.19 |
| 其中:利息收入 | 47,013,216.56 | 66,822,023.2 | 64,747,386.59 | 63,350,787.56 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 19,297,130.89 | 41,312,956.01 | 17,463,116.07 | -32,509,512.31 |
| 加:投资收益 | 25,714,330.3 | 189,887,071.97 | 156,700,654.11 | 131,621,780.6 |
| 资产处置收益 | - | 173,234.04 | 81,330.68 | 68,411.54 |
| 资产减值损失(新) | - | -474,140.79 | -1,140,852.47 | -1,140,852.47 |
| 信用减值损失(新) | 47,222,906.65 | -4,863,034.89 | 22,621,190.37 | 20,954,411.68 |
| 其他收益 | 6,284,608.12 | 24,156,778.1 | 14,964,351.52 | 8,704,866.43 |
| 四、营业利润 | 473,047,371.89 | 2,157,753,144.21 | 1,255,128,353.42 | 833,428,316.11 |
| 加:营业外收入 | 1,193,017.18 | 18,595,316.98 | 17,768,694.95 | 16,707,318.28 |
| 减:营业外支出 | 69,961.08 | 14,091,909.84 | 12,490,833.61 | 1,092,800.86 |
| 五、利润总额 | 474,170,427.99 | 2,162,256,551.35 | 1,260,406,214.76 | 849,042,833.53 |
| 减:所得税费用 | 75,103,568.1 | 383,992,447.15 | 236,289,212.9 | 123,756,924.63 |
| 六、净利润 | 399,066,859.89 | 1,778,264,104.2 | 1,024,117,001.86 | 725,285,908.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 399,066,859.89 | 1,778,264,104.2 | 1,024,117,001.86 | 725,285,908.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 400,141,867.56 | 1,777,852,640.46 | 1,022,463,426.87 | 724,364,011.18 |
| 少数股东损益 | -1,075,007.67 | 411,463.74 | 1,653,574.99 | 921,897.72 |
| 扣除非经常损益后的净利润 | 357,359,475.7 | 1,561,257,018.02 | 859,256,809.58 | 620,630,136.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.44 | 1.93 | 1.11 | 0.78 |
| (二)稀释每股收益 | 0.44 | 1.93 | 1.11 | 0.78 |
| 九、综合收益总额 | 399,066,859.89 | 1,778,264,104.2 | 1,024,117,001.86 | 725,285,908.9 |
| 归属于母公司股东的综合收益总额 | 400,141,867.56 | 1,777,852,640.46 | 1,022,463,426.87 | 724,364,011.18 |
| 归属于少数股东的综合收益总额 | -1,075,007.67 | 411,463.74 | 1,653,574.99 | 921,897.72 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-28 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |